Clinical use of immunosuppressants in duchenne muscular dystrophy

Journal of Clinical Neuromuscular Disease

Volumn 12, Issue 1, 2010, Pages 1-21

  Iannitti, Tommaso ^a   Capone, Stefania ^b   Feder, David ^c   Palmieri, Beniamino ^b  

^a GLASGOW CALEDONIAN UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c FACULDADE DE MEDICINA DO ABC   (Brazil)

Author keywords

Duchenne; dystrophin; dystrophy; immunosuppressants

Indexed keywords

ARGININE; AZATHIOPRINE; CALCIUM; CYCLOPHILIN D; CYCLOSPORIN A; CYCLOSPORIN A [3 N METHYL DEXTRO ALANINE 4 N ETHYLVALINE]; DEFLAZACORT; DILTIAZEM; DYSTROPHIN; ETANERCEPT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MELOXICAM; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; N(G) NITROARGININE METHYL ESTER; NIFEDIPINE; NIMODIPINE; OXANDROLONE; PLACEBO; PREDNISOLONE; PREDNISONE; TACROLIMUS; VERAPAMIL; VITAMIN D;

ABDOMINAL PAIN; ALLERGY; ANKYLOSING SPONDYLITIS; ASTHMA; ATOPIC DERMATITIS; AUTOIMMUNE DISEASE; BACKACHE; BEHAVIOR CHANGE; BELL PALSY; BREATHING MUSCLE; CATARACT; CLINICAL TRIAL; COLD; COUGHING; CROHN DISEASE; DISEASE COURSE; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG SAFETY; DUCHENNE MUSCULAR DYSTROPHY; ENTERITIS; FEVER; GINGIVA OVERGROWTH; GROWTH RETARDATION; HAIR GROWTH; HEADACHE; HEART; HEART VENTRICLE HYPERTROPHY; HEPATITIS C; HIRSUTISM; HUMAN; HYPERTENSION; HYPOTENSION; INFLAMMATORY DISEASE; INJECTION SITE COLORATION; INJECTION SITE INFLAMMATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; JUVENILE RHEUMATOID ARTHRITIS; KIDNEY INJURY; LIVER INJURY; MONONUCLEOSIS; MOUSE; MUSCLE ATROPHY; MUSCLE CELL; MUSCULOSKELETAL SYSTEM INFLAMMATION; MYOBLAST; NAUSEA; NEPHROTIC SYNDROME; NEPHROTOXICITY; NONHUMAN; OBESITY; PEMPHIGUS; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; RASH; REVIEW; RHEUMATOID ARTHRITIS; SARCOIDOSIS; SIDE EFFECT; SKELETAL MUSCLE; ULCERATIVE COLITIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; UVEITIS; VASCULITIS; VERTEBRA FRACTURE; VITILIGO; VOMITING; WEAKNESS; WEIGHT GAIN;

ANIMALS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; MUSCULAR DYSTROPHY, DUCHENNE; TREATMENT OUTCOME;

EID: 77956442515     PISSN: 15220443     EISSN: 15371611     Source Type: Journal    
DOI: 10.1097/CND.0b013e3181d4a4f9     Document Type: Review

References (53)

1. Whitehead NP, Yeung EW, Allen DG. Muscle damage in mdx (dystrophic) mice: role of calcium and reactive oxygen species. Clin Exp Pharmacol Physiol. 2006;33:657-662.
2. Gosselin LE, McCormick KM. Targeting the immune system to improve ventilator function in muscular dystrophy. Med Sci Sports Exerc. 2004;36:44-51.
3. Grounds MD, Radley HG, Gebski BL, et al. Implications of cross-talk between tumour necrosis factor and insulin-like growth factor-1 signaling in skeletal muscle. Clin Exp Pharmacol Physiol. 2008;35: 846-851.
4. Lebwohl M, Gower T. A safety assessment of topical calcineurin inhibitors in the treatment of atopic dermatitis. Medscape MedGenMed. 2006;8:8.
5. Cook BA, Warshaw EM. Role of topical calcineurin inhibitors in the treatment of seborrheic dermatitis: a review of pathophysiology, safety, and efficacy. Am J Clin Dermatol. 2009;10:103-118.
6. Parsons SA, Millay DP, Sargent MA, et al. Genetic disruption of calcineurin improves skeletal muscle pathology and cardiac disease in a mouse model of limb-girdle muscular dystrophy. J Biol Chem. 2007; 282:10068-10078.
7. Flisiak R, Horban A, Gallay P, et al. The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus. Hepatology. 2008; 7:817-826.
8. Ptak RG, Gallay PA, Jochmans D, et al. Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent. Antimicrob Agents Chemother. 2008; 52:1302-1317.
9. Reutenauer J, Dorchies OM, Patthey-Vuadens O, et al. Investigation of Debio 025, a cyclophilin inhibitor, in the dystrophic mdx mouse, a model for Duchenne muscular dystrophy. Br J Pharmacol. 2008;155:574-584.
10. Millay DP, Sargent MA, Osinska H, et al. Genetic and pharmacologic inhibition of mitochondrial-dependent necrosis attenuates muscular dystrophy. Nat Med. 2008;14:442-447.
11. Goncxalves SC, D́az-Serrano KV, de Queiroz AM, et al. Gingival overgrowth in a renal transplant recipient using cyclosporine A. J Dent Child (Chic). 2008;75: 313-317.
12. Hogan WJ, Storb R. Use of cyclosporine in hematopoietic cell transplantation. Transplant Proc. 2004; 36(Suppl 2S):S367-S371.
13. Marx M, Weber M, Merkel F, et al. Additive effects of calcium antagonists on cyclosporin A-induced inhibition of T-cell proliferation. Nephrol Dial Transplant. 1990;5:1038-1044.
14. De Luca A, Nico B, Liantonio A, et al. A multidisciplinary evaluation of the effectiveness of cyclosporine a in dystrophic mdx mice. Am J Pathol. 2005;166:477-489.
15. Stupka N, Gregorevic P, Plant DR, et al. The calcineurin signal transduction pathway is essential for successful muscle regeneration in mdx dystrophic mice. Acta Neuropathol. 2004;107:299-310.
16. Stupka N, Schertzer JD, Bassel-Duby R, et al. Stimulation of calcineurin Alpha activity attenuates muscle pathophysiology in mdx dystrophic mice. Am J Physiol Regul Integr Comp Physiol. 2008;294: R983-R992.
17. Spencer CM, Goa KL, Gillis JC. Tacrolimus. An update of its pharmacology and clinical efficacy in the management of organ transplantation. Drugs. 1997;54:925-975.
18. Pierno S, Nico B, Burdi R, et al. Role of tumour necrosis factor alpha, but not of cyclo-oxygenase-2-derived eicosanoids, on functional and morphological indices of dystrophic progression in mdx mice: a pharmacological approach. Neuropathol Appl Neurobiol. 2007;33:344-359.
19. Hodgetts S, Radley H, Davies M, et al. Reduced necrosis of dystrophic muscle by depletion of host neutrophils, or blocking TNFalpha function with etanercept in mdx mice. Neuromuscul Disord. 2006;16:591-602.
20. Grounds MD, Torrisi J. Anti-TNFalpha (Remicade) therapy protects dystrophic skeletal muscle from necrosis. FASEB J. 2004;18:676-682.
21. Anderson JE, McIntosh LM, Poettcker R. Deflazacort but not prednisone improves both muscle repair and fiber growth in diaphragm and limb muscle in vivo in the mdx dystrophic mouse. Muscle Nerve. 1996; 19:1576-1585.
22. Archer JD, Vargas CC, Anderson JE. Persistent and improved functional gain in mdx dystrophic mice after treatment with L-arginine and deflazacort. FASEB J. 2006;20:738-740.
23. St-Pierre SJ, Chakkalakal JV, Kolodziejczyk SM, et al. Glucocorticoid treatment alleviates dystrophic myofiber pathology by activation of the calcineurin/ NF-AT pathway. FASEB J. 2004;18:1937-1939.
24. Marques MJ, Oggiam DS, Barbin IC, et al. Long-term therapy with deflazacort decreases myocardial fibrosis in mdx mice. Muscle Nerve. 2009;40:466-468.
25. Weller B, Massa R, Karpati G, et al. Glucocorticoids and immunosuppressants do not change the prevalence of necrosis and regeneration in mdx skeletal muscles. Muscle Nerve. 1991;14:771-774.
26. Strober J, Rando T. Mycophenolate mofetil's beneficial effects on skeletal muscle in the mdx mouse. Neuromuscul Disord. 2007;17:803.
27. Biggar WD, Gingras M, Fehlings DL, et al. Deflazacort treatment of Duchenne muscular dystrophy. J Pediatr. 2001;138:45-50.
28. Biggar WD, Politano L, Harris VA, et al. Deflazacort in Duchenne muscular dystrophy: a comparison of two different protocols. Neuromuscul Disord. 2004;14: 476-482.
29. Biggar WD, Harris VA, Eliasoph L, et al. Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscul Disord. 2006;16:249-255.
30. Houde S, Filiatrault M, Fournier A, et al. Deflazacort use in Duchenne muscular dystrophy: an 8-year follow-up. Pediatr Neurol. 2008;38:200-206.
31. Manzur AY, Kuntzer T, Pike M, et al. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev. 2008;1:CD003725.
32. Balaban B, Matthews DJ, Clayton GH, et al. Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: long-term effect. Am J Phys Med Rehabil. 2005;84:843-850.
33. Dubowitz V, Kinali M, Main M, et al. Remission of clinical signs in early Duchenne muscular dystrophy on intermittent low-dosage prednisolone therapy. Eur J Paediatr Neurol. 2002;6:153-159.
34. Markham LW, Spicer RL, Khoury PR, et al. Steroid therapy and cardiac function in Duchenne muscular dystrophy. Pediatr Cardiol. 2005;26:768-771.
35. Griggs RC, Griggs RC, Moxley RT 3rd, et al. Duchenne dystrophy: randomized, controlled trial of prednisone (18 months) and azathioprine (12 months). Neurology. 1993;43:520-527.
36. Markham LW, Michelfelder EC, Border WL, et al. Abnormalities of diastolic function precede dilated cardiomyopathy associated with Duchenne muscular dystrophy. J Am Soc Echocardiogr. 2006;19: 865-871.
37. Kirschner J, Schessl J, Ihorst G, et al; Muskeldystrophie Netzwerk MD-NET. Treatment of Duchenne muscular dystrophy with cyclosporin A - A randomized, double-blind, placebo controlled trial. Neuropediatrics. 2008;44:39.
38. Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol. 2009;4:481-508.
39. Sharma KR, Mynhier MA, Miller RG. Cyclosporine increases muscular force generation in Duchenne muscular dystrophy. Neurology. 1993;43:527-532.
40. Straathof CS, Overweg-PlandsoenWC, van den Burg GJ, et al. Prednisone 10 days on/10 days off in patients with Duchenne muscular dystrophy. J Neurol. 2009; 256:768-773.
41. Skuk D, Goulet M, Roy B, et al. First test of a-highdensity injection-protocol for myogenic cell transplantation throughout large volumes of muscles in a Duchenne muscular dystrophy patient: eighteen months follow-up. Neuromuscul Disord. 2007;17: 38-46.
42. Balagopal P, Olney R, Darmaun D, et al. Oxandrolone enhances skeletal muscle myosin synthesis and alters global gene expression profile in Duchenne muscular dystrophy. Am J Physiol Endocrinol Metab. 2006;290:E530-E539.
43. Fenichel G, Pestronk A, Florence J, et al. A beneficial effect of oxandrolone in the treatment of Duchenne muscular dystrophy: a pilot study. Neurology. 1997; 48:1225-1226.
44. Fenichel GM, Griggs RC, Kissel J, et al. A randomized efficacy and safety trial of oxandrolone in the treatment of Duchenne dystrophy. Neurology. 2001;56: 1075-1079.
45. Moxley RT 3rd, Ashwal S, Pandya S, et al; Quality Standards Subcommittee of the American Academy of Neurology; Practice Committee of the Child Neurology Society. Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology. 2005;64: 13-20.
46. Parker MH, Kuhr C, Tapscott SJ, et al. Hematopoietic cell transplantation provides an immune-tolerant platform for myoblast transplantation in dystrophic dogs. Mol Ther. 2008;16:1340-1346.
47. Kamper A, Rodemann HP. Alterations of protein degradation and 2-D protein pattern in muscle cells of mdx and DMD origin. Biochem Biophys Res Commun. 1992,189:1484-1490.
48. Matthews W, Driscoll J, Tanaka K, et al. Involvement of the proteasome in various degradative processes in mammalian cells. Proc Natl Acad Sci USA. 1989, 86:2597-2601.
49. Gao Y, Lecker S, Post MJ, et al. Inhibition of ubiquitin-proteasome pathway-mediated I kappa B alpha degradation by a naturally occurring antibacterial peptide. J Clin Invest. 2000;106:439-448.
50. Bonuccelli G, Sotgia F, Schubert W, et al. Proteasome inhibitor (MG-132) treatment of mdx mice rescues the expression and membrane localization of dystrophin and dystrophin-associated proteins. Am J Pathol. 2003;163:1663-1675.
51. Assereto S, Stringara S, Sotgia F, et al. Pharmacological rescue of the dystrophin-glycoprotein complex in Duchenne and Becker skeletal muscle explants by proteasome inhibitor treatment. Am J Physiol Cell Physiol. 2006;290:C577-C582.
52. Bonuccelli G, Sotgia F, Capozza F, et al. Localized treatment with a novel FDA-approved proteasome inhibitor blocks the degradation of dystrophin and dystrophin-associated proteins in mdx mice. Cell Cycle. 2007;6:1242-1248.
53. Gazzerro E, Assereto S, Bonetto A, et al. Therapeutic potential of proteasome inhibition in duchenne and becker muscular dystrophies. Am J Pathol. 2010;19.